Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29335643 | 1.00 | PDK1 (0.47) | PDK1ADORA2AADORA1AKT1ALOX5AP | |
| SCHEMBL27731539 | 0.81 | PDK1 (0.34) | PDK1 | |
| SCHEMBL29221314 | 0.81 | ALDH1A1 (0.34) | — | |
| SCHEMBL22732907 | 0.81 | CHEK1 (0.35) | PRKCGPRKCBPRKCAPRKCHPRKCZ | |
| SCHEMBL29221316 | 0.81 | AKT1 (0.31) | AKT1 | |
| SCHEMBL29221312 | 0.81 | ALDH1A1 (0.34) | — | |
| SCHEMBL3403132 | 0.81 | CHEK1 (0.35) | PRKCGPRKCBPRKCAPRKCHPRKCZ | |
| SCHEMBL29221319 | 0.81 | AKT1 (0.31) | AKT1 | |
| SCHEMBL9779313 | 0.81 | KDM4E (0.31) | PDK1 | |
| SCHEMBL27731603 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425743-A | Benzo heterocyclic compound serving as PI3K alpha kinase inhibitor, and preparation method and application thereof | 贵州医科大学 | 2023-07-14 | — | — | CN | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| CN-116425743-A | Benzo heterocyclic compound serving as PI3K alpha kinase inhibitor, and preparation method and application thereof | 贵州医科大学 | 2023-07-14 | — | — | CN | disclosed |
| US-11390609-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-07-19 | — | — | US | disclosed |
| CN-111377911-B | Morpholine benzamide compound and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111377911-A | Morpholine benzamide compound and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-106488916-A | The new 2,5 substituted miazines as PDE inhibitor | 格吕伦塔尔有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | disclosed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390609-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | ROCK1, ROCK2, RHOA | PDK1 2039/4885ADORA2A 3184/4885ADORA1 2891/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | PDK1 1027/4885ADORA2A 208/4885ADORA1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.